Celgene’s Abraxane Recommended for NHS Wales

The Welsh government has recommended Celgene’s Abraxane to treat pancreatic cancer on the National Health Service (NHS) in Wales. Specifically, Abraxane (nab-paclitaxel) has been approved by the All Wales Medicines Strategy Group as an option for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Mark

Continue Reading